Riluzole is a glutamate antagonist. Riluzole has been reported to confer a survival benefit to the subgroup of patients with bulbar-onset amyotrophic lateral sclerosis.

Glutamate Inhibitor. The efficacy of riluzole in amyotrophic lateral sclerosis remains unclear.

Absorption: High-fat meal decreases AUC by 20% and peak blood levels by 45%.
Protein binding, plasma: 96%, primarily to albumin and lipoproteins
Distribution: Vd ~3.4 L/kg
Metabolism: Hepatic via CYP1A2 and UGT-HP4
Bioavailability: Oral ~60%
Half-life elimination: 12 hours
Excretion: Urine (90%; 2% as unchanged drug) and feces (5%)

Hypersensitivity to riluzole

C

No human data available to assess risk of infant harm or effects on milk production; caution advised while breastfeeding.

asthenia, elevation of serum transaminases, worsening of spasticity, gastrointestinal symptoms, and blood pressure elevations.

Amyotrophic lateral sclerosis: 50 mg PO BID

There are no dosage adjustments provided in the manufacturer's labeling.

There are no dosage adjustments provided in the manufacturer's labeling.